Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BBIO BridgeBio Pharma Inc
- Stocks
- Healthcare
- NASDAQ: BBIO
Price (delayed)
$33.84
Market cap
$6.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.55
Enterprise value
$8.24B
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in
Highlights
BBIO's equity has dropped by 57% year-on-year and by 12% since the previous quarter
The gross profit has contracted by 44% from the previous quarter and by 44% YoY
Key stats
What are the main financial stats of BBIO
Market
Valuations
Earnings
Shares outstanding
189.88M
Market cap
$6.43B
Enterprise value
$8.24B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
50.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.67
Revenue
$127.42M
Gross profit
$121.5M
Operating income
-$697.69M
Net income
-$667.97M
EBIT
-$548.86M
EBITDA
-$539.06M
Free cash flow
-$500.66M
Per share
Balance sheet
Liquidity
EPS
-$3.55
EPS diluted
-$3.55
Free cash flow per share
-$2.63
Book value per share
-$8.67
Revenue per share
$0.67
TBVPS
$4.49
Total assets
$881.64M
Total liabilities
$2.52B
Debt
$2.36B
Equity
-$1.65B
Working capital
$543.07M
Debt to equity
-1.43
Current ratio
4.57
Quick ratio
4.31
Net debt/EBITDA
-3.37
Margins
Efficiency
Dividend
EBITDA margin
-423.1%
Gross margin
95.4%
Net margin
-524.2%
Operating margin
-547.6%
Return on assets
-82%
Return on equity
N/A
Return on invested capital
-26%
Return on capital employed
-75.2%
Return on sales
-430.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BBIO stock price
How has the BridgeBio Pharma stock price performed over time
Intraday
0.3%
1 week
-0.97%
1 month
-0.03%
1 year
9.02%
YTD
23.32%
QTD
-2.11%
Financial performance
How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$127.42M
Gross profit
$121.5M
Operating income
-$697.69M
Net income
-$667.97M
Gross margin
95.4%
Net margin
-524.2%
BBIO's operating margin has shrunk by 149% YoY and by 105% QoQ
BBIO's net margin has dropped by 117% since the previous quarter and by 113% year-on-year
BBIO's operating income is down by 45% year-on-year and by 18% since the previous quarter
The gross profit has contracted by 44% from the previous quarter and by 44% YoY
Price vs fundamentals
How does BBIO's price correlate with its fundamentals
Growth
What is BridgeBio Pharma's growth rate over time
Valuation
What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
50.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.67
BBIO's EPS is down by 23% since the previous quarter and by 10% year-on-year
BBIO's equity has dropped by 57% year-on-year and by 12% since the previous quarter
The stock's price to sales (P/S) is 77% less than its 5-year quarterly average of 224.2 but 71% more than its last 4 quarters average of 29.6
BridgeBio Pharma's revenue has decreased by 43% from the previous quarter and by 42% YoY
Efficiency
How efficient is BridgeBio Pharma business performance
BBIO's ROS has dropped by 120% since the previous quarter and by 108% year-on-year
The ROA has contracted by 23% from the previous quarter but it has grown by 2.7% YoY
The ROIC has contracted by 17% from the previous quarter and by 2.8% YoY
Dividends
What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BBIO.
Financial health
How did BridgeBio Pharma financials performed over time
BBIO's total assets is 65% smaller than its total liabilities
BBIO's total liabilities is up by 34% YoY and by 6% QoQ
BridgeBio Pharma's quick ratio has decreased by 19% YoY and by 2.9% from the previous quarter
BBIO's equity has dropped by 57% year-on-year and by 12% since the previous quarter
BBIO's debt is up by 36% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.